Combining Induced Pluripotent Stem Cell with Next Generation Sequencing Technology to Gain New Insights into Pathobiology and Treatment of Pulmonary Arterial Hypertension

PVRI Member Authors: Marlene Rabinovitch


It was an honor to give the Giles F. Filley Lecture. Dr. Filley was cofounder of the Aspen Lung Conference and a master clinician and scientist with major contributions to the field of acid base balance. He developed “caribicarb,” a combination of calcium carbonate and sodium bicoarbonate. He also contributed to our understanding of the pathophysiology of chronic obstructive pulmonary disease and emphysema through his many publications including one in which he described the elastic properties of the different lobes of the human lung.

This manuscript describes using induced pluripotent stem cells (iPSCs) combined with next generation sequencing to gain new information about the pathobiology of pulmonary arterial hypertension (PAH) and to discover ways in which future therapies for this disorder might be personalized. The studies we propose represent a team effort between our laboratory, that of Dr. Joseph Wu in the Department of Medicine at Stanford University who pioneered the derivation and characterization of endothelial cells from iPSCs, and that of Dr. Michael Snyder in the Department of Genetics, who developed next generation sequencing approaches for personalized medicine.

Published in:

Pulmonary Circulation Vol 3: No 1 cover image

March 2013

Pulmonary Circulation Vol 3: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI